Axicabtagene ciloleucel in large B cell ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial.
Auteur(s) :
Houot, R. [Auteur]
Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer [MOBIDIC]
Bachy, E. [Auteur]
Cartron, G. [Auteur]
Gros, F. X. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Oberic, L. [Auteur]
Gastinne, T. [Auteur]
Feugier, P. [Auteur]
Duléry, R. [Auteur]
Thieblemont, C. [Auteur]
Joris, M. [Auteur]
Jardin, F. [Auteur]
Choquet, S. [Auteur]
Casasnovas, O. [Auteur]
Brisou, G. [Auteur]
Cheminant, M. [Auteur]
Bay, J. O. [Auteur]
Gutierrez, F. L. [Auteur]
Menard, C. [Auteur]
Tarte, K. [Auteur]
Delfau, M. H. [Auteur]
Portugues, C. [Auteur]
Itti, E. [Auteur]
Palard-Novello, X. [Auteur]
Blanc-Durand, P. [Auteur]
Al Tabaa, Y. [Auteur]
Bailly, C. [Auteur]
Laurent, C. [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Lemonnier, F. [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer [MOBIDIC]
Bachy, E. [Auteur]
Cartron, G. [Auteur]
Gros, F. X. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Oberic, L. [Auteur]
Gastinne, T. [Auteur]
Feugier, P. [Auteur]
Duléry, R. [Auteur]
Thieblemont, C. [Auteur]
Joris, M. [Auteur]
Jardin, F. [Auteur]
Choquet, S. [Auteur]
Casasnovas, O. [Auteur]
Brisou, G. [Auteur]
Cheminant, M. [Auteur]
Bay, J. O. [Auteur]
Gutierrez, F. L. [Auteur]
Menard, C. [Auteur]
Tarte, K. [Auteur]
Delfau, M. H. [Auteur]
Portugues, C. [Auteur]
Itti, E. [Auteur]
Palard-Novello, X. [Auteur]
Blanc-Durand, P. [Auteur]
Al Tabaa, Y. [Auteur]
Bailly, C. [Auteur]
Laurent, C. [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Lemonnier, F. [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
Titre de la revue :
Nature Medicine
Nom court de la revue :
Nat Med
Numéro :
29
Pagination :
2593–2601
Date de publication :
2023-09-14
ISSN :
1546-170X
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for ...
Lire la suite >Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem cell transplantation (ASCT); however, in clinical practice, roughly half of patients with R/R LBCL are deemed unsuitable candidates for ASCT. The efficacy of axi-cel remains to be ascertained in transplant-ineligible patients. ALYCANTE, an open-label, phase 2 study, evaluated axi-cel as a second-line therapy in 62 patients with R/R LBCL who were considered ineligible for ASCT. The primary end point was investigator-assessed complete metabolic response at 3 months from the axi-cel infusion. Key secondary end points included progression-free survival, overall survival and safety. The study met its primary end point with a complete metabolic response of 71.0% (95% confidence interval, 58.1–81.8%) at 3 months. With a median follow-up of 12.0 months (range, 2.1–17.9), median progression-free survival was 11.8 months (95% confidence interval, 8.4–not reached) and overall survival was not reached. There was no unexpected toxicity. Grade 3–4 cytokine release syndrome and neurologic events occurred in 8.1% and 14.5% of patients, respectively. These results support axi-cel as second-line therapy in patients with R/R LBCL ineligible for ASCTLire moins >
Lire la suite >Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem cell transplantation (ASCT); however, in clinical practice, roughly half of patients with R/R LBCL are deemed unsuitable candidates for ASCT. The efficacy of axi-cel remains to be ascertained in transplant-ineligible patients. ALYCANTE, an open-label, phase 2 study, evaluated axi-cel as a second-line therapy in 62 patients with R/R LBCL who were considered ineligible for ASCT. The primary end point was investigator-assessed complete metabolic response at 3 months from the axi-cel infusion. Key secondary end points included progression-free survival, overall survival and safety. The study met its primary end point with a complete metabolic response of 71.0% (95% confidence interval, 58.1–81.8%) at 3 months. With a median follow-up of 12.0 months (range, 2.1–17.9), median progression-free survival was 11.8 months (95% confidence interval, 8.4–not reached) and overall survival was not reached. There was no unexpected toxicity. Grade 3–4 cytokine release syndrome and neurologic events occurred in 8.1% and 14.5% of patients, respectively. These results support axi-cel as second-line therapy in patients with R/R LBCL ineligible for ASCTLire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-10-20T05:37:43Z
2024-05-15T07:29:13Z
2024-05-15T07:29:13Z
Annexes
- document
- Accès libre
- -
- Accéder au document